2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Treatment Considerations, Combination Therapy, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Pharmacology, Radiation Therapy, Workforce, Adverse Events, Artificial Intelligence (AI), Generative AI, Natural Language Processing, Biological Processes, Immune Mechanism, Molecular Biology, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Practice Models, Quality Improvement, Quality of Care, Systems-Based Hematology, Diseases, Infectious Diseases, Viral, Bacterial, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, CLL, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

2710 Real-world outcomes of CAR-T cell therapy in relapsed/refractory follicular lymphoma: A joint EBMT lymphoma working party and cellular therapy & immunobiology working party study

Leyre Bento, MD, PhD, Maud Ngoya2, Vanderson Geraldo Rocha, MD PhD3, Joaquín Martínez-López4, Edouard Forcade, MD, PhD5, Didier Blaise, MD6, Guillaume Cartron, MD7, Malte Von Bonin8, Vladan Vucinic, MD9, Thomas Pabst10, Tom Van Meerten, MD, PhD11, Christof Scheid, MD12, Charles Crawley, MD FRCP FRCpath13, Emmanuel Gyan, MD, PhD14, Anne Huynh15, Michael Loschi, MD, PhD16, Johannes Clausen17, Robert Pytlik18, Stefania Bramanti, MD19, Peter Brossart20, Paolo Corradini21, Sridhar Chaganti22, Marie-Thérèse Rubio23, Guillaume Dachy24, Emanuele Angelucci25, Philipp Nakov, MD26, Annalisa Ruggeri, MD27, Charalampia Kyriakou, MD, PhD28, Silvia Montoto29, Ali Bazarbachi30
1 Hematology Department, Son Espases University Hospital, IdISBa, Palma, Spain
2 European Society for Blood and Marrow Transplantation, Paris Study Unit, Hôpital Saint-Antoine, Paris, France, Paris, France
3 Hospital das Clinicas da FMUSP, Sao Paulo, Brazil
4 Hospital 12 Octubre, imas12, Complutense University, CNIO, Madrid, Spain
5 Service d'Hématologie Clinique et Thérapie Cellulaire, CHU Bordeaux, Bordeaux, France
6 Instituto Paoli-Calmettes, Marseille, France
7 Hematology Department, CHU Montpellier, Montpellier, France
8 Technical University Dresden, Dresden, Germany
9 University of Leipzig Medical Center, Leipzig, Germany
10 University Hospital Bern, University of Bern, Bern, Switzerland
11 University Medical Center Groningen, Groningen, Netherlands
12 University of Cologne, Cologne, Germany
13 Addenbrookes Hospital, Cambridge, United Kingdom
14 Hopital Bretonneau, Paris, France
15 CHU Institut Universitaire du Cancer, Toulouse, France
16 CHU Nice, Nice, France
17 Ordensklinikum Linz Elisabethinen, Linz, Austria
18 Institute of Haematology and Blood Transfusion, Prague, Czech Republic
19 IRCCS Isituto Clinico Humanitas Rozzano, Rozzano, Italy
20 University Hospital Bonn, Bonn, Germany
21 University of Milan and Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
22 Birmingham Centre for Cellular Therapy and Transplant, Birmingham, United Kingdom
23 CHRU de Nancy, Nancy, France
24 Cliniques Universitaires St. Luc, Brussels, Belgium
25 Hematology and Cellular Therapy, IRCCS Ospedale Policlinico San Martino, Genova, Italy
26 University Medical Center Schleswig-Holstein, Kiel, Germany
27 IRCCS San Raffaele Scientific Institute, Milan, Italy
28 University College London Hospitals NHS Foundation Trust London, London, United Kingdom
29 St Bartholomew's Hospital, Barts Health NHS Trust, London, United Kingdom
30 American University of Beirut Medical Center, Beirut, Lebanon

Introduction

Follicular lymphoma (FL) is the most common indolent non-Hodgkin lymphoma. Relapsed/refractory (R/R) FL is usually considered incurable with conventional therapies. The management after ≥2 lines is highly heterogenous, reflecting the lack of a standard approach. Axicabtagene ciloleucel (axi-cel), tisagenlecleucel (tisa-cel) and, more recently, lisocabtagene maraleucel (liso-cel) have been approved based on the results of the pivotal trials ZUMA-5, ELARA and TRANSCEND-FL, respectively. These studies demonstrated durable responses with manageable toxicity in heavily pretreated populations. However, real-world data on CAR-T cell therapy for FL remain limited. Therefore, we evaluated the efficacy and safety of commercial CAR-T cell therapy for R/R FL using data from the EBMT registry.

 

Patients and methods

This retrospective multicenter study included patients with R/R FL treated with approved CAR-T cell therapy from 2018 to 2023 and reported to the EBMT registry. Patients who received academic CAR-T cell therapy as compassionate use, CAR-T product within a clinical trial or had transformed lymphoma were excluded. The primary endpoints were efficacy including best overall response (BOR), complete response rate (CRR), progression-free survival (PFS) and overall survival (OS). Secondary endpoints included non-relapse mortality (NRM), incidence of cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome (ICANS).

 

Results

A total of 267 patients were included. The median age at CAR-T infusion was 63 years (range 33–82) and 64% were male. The median interval from diagnosis to CAR-T infusion was 55.5 months and it was <24 months in 19.5% of the patients. At the time of CAR-T infusion, disease status pre-CAR-T was refractory in 65.5% of patients, stable disease in 11%, partial response in 17.5% and complete response in 6% of the patients. Overall, 160 (60%) patients received tisa-cel and 107 (40%) axi-cel. Ninety-six patients (36%) had previously received autologous stem cell transplantation. Most of the patients (97%) received cyclophosphamide/fludarabine as lymphodepletion regimen. The BOR on day 100 and 1 year was 74% (95%CI 68-80) and 92% (95%CI 87-95), respectively, while the corresponding CRR was 65% (95%CI 59-71) and 80% (95%CI 74-84). After a median follow up of 22 months, PFS at 2 years was 60% (95%CI 53-67) and OS at 2 years 76% (95%CI 68-81). Seventy-eight patients relapsed/progressed with a median time from CAR-T infusion to progression of 146 days (range 28-1077). One-hundred and forty-six patients (58%) had CRS (grade ≥3 in 4%) with a median onset of 2 days (range 0-23). ICANS developed in 62 patients (26%) including grade ≥3 in 5%, with a median onset of 5 days (range 1-37). The cumulative incidence of NRM at 2 years was 11% (95%CI 6-16). Among the 59 deaths, the primary causes were disease relapse (31 patients, 54%), treatment-related mortality (11 patients, 19%), and other causes (17 patients, 29%).

 

Conclusions

To our knowledge, this is the largest real-world study of CAR-T cell therapy in patients with R/R FL. Both axi-cel and tisa-cel demonstrated high efficacy with durable responses and survival outcomes comparable to those reported in the pivotal trials. Notably, in our series a lower incidence of CRS and ICANS was found in comparison with that reported in previous studies, probably reflecting improvements in the prevention of such complications in recent years. These results support the effectiveness and safety of commercial CAR-T cell therapy in routine clinical practice and reinforce its role as a standard treatment option for patients with R/R FL. Further studies are warranted to identify patients most likely to benefit from CAR-T therapy and to define its optimal sequencing within the evolving therapeutic landscape of FL.

Leyre Bento, MD, PhD: Kite/Gilead, BMS, J&J, Lilly, Abbvie, Roche, Astrazeneca, Sanofi, Takeda, Novartis, Incyte, BeOne, Jazz, BMS - Consultancy (Includes expert testimony)